<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>SILDENAFILÂ - sildenafil citrateÂ injection, solutionÂ </strong><br>AuroMedics Pharma LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use sildenafil injection safely and effectively. See full prescribing information for sildenafil injection.<br><br>SILDENAFIL injection, for intravenous use<br><br>Initial U.S. Approval: 1998</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div><p class="Highlighta">CONTRAINDICATIONSÂ <a href="#Section_4">(4)</a>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  04/2015 </p></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">Sildenafil is a phosphodiesterase-5 (PDE-5) inhibitor indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (PAH) (WHO Group I) in adults to improve exercise ability and delay clinical worsening. Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with NYHA Functional Class II-III symptoms. Etiologies were idiopathic (71%) or associated with connective tissue disease (25%). <a href="#Section_1">(1)</a> </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<ul class="Disc"><li>Injection: 10 mg three times a day administered as an intravenous bolus injection <a href="#Section_2.1">(2.2)</a>
</li></ul>
<a href="#Section_2.1"></a>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>
<span class="Italics">Injection:</span> 10 mg/12.5 mL in a single use vial <a href="#Section_3">(3)</a>
</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Use with organic nitrates or riociguat <a href="#Section_4">(4)</a>
</li>
<li>History of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reaction</span> to sildenafil or any component of the injection <a href="#Section_4">(4)</a>
</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Increased mortality with increasing doses in pediatric patients. Not recommended for use in pediatric patients.Â <a href="#Section_5.1">(5.1)</a>
</li>
<li>Vasodilation effects may be more common in patients with <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> or on antihypertensive therapy.Â <a href="#Section_5.2">(5.2)</a>
</li>
<li>Use in pulmonary veno-occlusive disease may cause <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> and is not recommended.Â <a href="#Section_5.3">(5.3)</a>
</li>
<li>Hearing or <span class="product-label-link" type="condition" conceptid="373786" conceptname="Abnormal vision">visual impairment</span>: Seek medical attention if sudden decrease or <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> or hearing occurs. <a href="#Section_5.5">(5.5</a>,Â <a href="#Section_5.6">5.6)</a>
</li>
<li><span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary hypertension secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span>: Sildenafil may cause serious vaso-occlusive crises. <a href="#Section_5.9">(5.9)</a>
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions greater than or equal to 3% and more frequent than placebo were <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">dyspepsia</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, and <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span>. <a href="#Section_6.1">(6.1</a>, <a href="#Section_6.2">6.2)</a><br><br><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact AuroMedics Pharma LLC at 1-866-850-2876 or FDA at 1-800-FDA-1088 or </span><span class="Bold"><a href="http://www.fda.gov/medwatch">www.fda.gov/medwatch</a></span><span class="Bold">.</span> </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc">
<li>Concomitant alpha-blockers or amlodipine: Note additive blood pressure lowering effects.Â <a href="#Section_7">(7)</a>
</li>
<li>Use with ritonavir and other potent CYP3A inhibitors: Not recommended.Â <a href="#Section_7">(7,</a>Â <a href="#Section_12.3">12.3)</a>
</li>
<li>Concomitant PDE-5 inhibitors: Avoid use with Viagra or other PDE-5 inhibitors. <a href="#Section_5.7">(5.7)</a>
</li>
</ul></div>
</div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.2 Sildenafil Injection</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1 Mortality with Pediatric Use</a></h2>
<h2><a href="#section-5.2" class="toc">5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></a></h2>
<h2><a href="#section-5.3" class="toc">5.3 Worsening Pulmonary Vascular Occlusive Disease</a></h2>
<h2><a href="#section-5.4" class="toc">5.4 <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5 Visual Loss</a></h2>
<h2><a href="#section-5.6" class="toc">5.6 <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></a></h2>
<h2><a href="#section-5.7" class="toc">5.7 Combination with other PDE-5 Inhibitors</a></h2>
<h2><a href="#section-5.8" class="toc">5.8 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></a></h2>
<h2><a href="#section-5.9" class="toc">5.9 Vaso-occlusive Crisis in Patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension Secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1 Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2 Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-8" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-8.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-8.2" class="toc">8.2 Labor and Delivery</a></h2>
<h2><a href="#section-8.3" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-8.4" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-8.5" class="toc">8.5 Geriatric Use</a></h2>
<h2><a href="#section-8.6" class="toc">8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></a></h2>
<h2><a href="#section-8.7" class="toc">8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></a></h2>
<h1><a href="#section-9" class="toc">10 OVERDOSAGE</a></h1>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.2 Pharmacodynamics</a></h2>
<h2><a href="#section-11.3" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="Section_1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">Sildenafil injection is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span> (WHO Group I) in adults to improve exercise ability and delay clinical worsening. The delay in clinical worsening was demonstrated when sildenafil injection was added to background epoprostenol therapy <span class="Italics">[<a href="#Section_14">see Clinical Studies (14)</a>]</span>. </p>
<br><p>Studies establishing effectiveness were short-term (12 to 16 weeks), and included predominately patients with New York Heart Association (NYHA) Functional Class II-III symptoms and idiopathic etiology (71%) or associated with connective tissue disease (CTD) (25%).</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="Section_2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.2 Sildenafil Injection</h2>
<p class="First">Sildenafil injection is for the continued treatment of patients with PAH who are currently prescribed oral sildenafil and who are temporarily unable to take oral medication.<br><br>The recommended dose is 10 mg administered as an intravenous bolus injection three times a day. The dose of sildenafil injection does not need to be adjusted for body weight.<br><br>A 10 mg dose of sildenafil injection is predicted to provide pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="Section_3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<br><p class="First"><span class="Bold">Sildenafil</span><span class="Bold"> Injection</span><br><br>Single use vial containing 10 mg/12.5 mL of sildenafil.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="Section_4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<br><p class="First">Sildenafil injection is contraindicated in patients with: </p>
<ul class="Disc">
<li>Concomitant use of organic nitrates in any form, either regularly or intermittently, because of the greater risk of <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> <span class="Italics">[<a href="#Section_5.2">see Warnings and Precautions (5.2)</a>]</span>. </li>
<li style="border-left:1px solid;">Concomitant useÂ <span class="XmChange">of</span> riociguat, a guanylate cyclase stimulator. PDE5 inhibitors, including sildenafil, may potentiate the hypotensive effects of riociguat.</li>
<li>Known <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to sildenafil or any component of the injection. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reaction</span>, has been reported in association with the use of sildenafil.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="Section_5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1 Mortality with Pediatric Use</h2>
<br><p class="First">In a long-term trial in pediatric patients with PAH, an increase in mortality with increasing sildenafil dose was observed. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Deaths</span> were first observed after about 1 year and causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were typical of patients with PAH. Use of sildenafil, particularly chronic use, is not recommended in children <span class="Italics">[<a href="#Section_8.4">see Use in Specific Populations (8.4)</a>].</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2 <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span></h2>
<br><p class="First">Sildenafil has vasodilatory properties, resulting in mild and transient decreases in blood pressure. Before prescribing sildenafil, carefully consider whether patients with certain underlying conditions could be adversely affected by such vasodilatory effects (e.g., patients on antihypertensive therapy or with resting <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span> [BP less than 90/50], fluid depletion, severe left ventricular outflow obstruction, or <span class="product-label-link" type="condition" conceptid="434633" conceptname="Disorder of autonomic nervous system">autonomic dysfunction</span>). Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3 Worsening Pulmonary Vascular Occlusive Disease</h2>
<br><p class="First">Pulmonary vasodilators may significantly worsen the cardiovascular status of patients with pulmonary veno-occlusive disease (PVOD). Since there are no clinical data on administration of sildenafil to patients with veno-occlusive disease, administration of sildenafil to such patients is not recommended. Should signs of <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> occur when sildenafil is administered, consider the possibility of associated PVOD.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4 <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span></h2>
<p class="First">The incidence of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> was 13% in patients taking sildenafil with PAH secondary to CTD. This effect was not seen in idiopathic PAH (sildenafil 3%, placebo 2%) patients. The incidence of <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">epistaxis</span> was also higher in sildenafil-treated patients with a concomitant oral vitamin K antagonist (9% versus 2% in those not treated with concomitant vitamin K antagonist).<br><br>The safety of sildenafil is unknown in patients with <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> disorders or active <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulceration</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5 Visual Loss</h2>
<p class="First">When used to treat <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, non-arteritic anterior <span class="product-label-link" type="condition" conceptid="373487" conceptname="Ischemic optic neuropathy">ischemic optic neuropathy</span> (NAION), a cause of decreased vision including permanent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span>, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including sildenafil. Most, but not all, of these patients had underlying anatomic or vascular risk factors for developing NAION, including but not necessarily limited to: low cup to disc ratio (â€œcrowded discâ€?), age over 50, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, <span class="product-label-link" type="condition" conceptid="432867" conceptname="Hyperlipidemia">hyperlipidemia</span> and smoking. Based on published literature, the annual incidence of NAION is 2.5 to 11.8 cases per 100,000 males aged â‰¥ 50 per year in the general population. An observational study evaluated whether recent, episodic use of PDE5 inhibitors (as a class), typical of <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span> treatment, was associated with acute onset of NAION. The results suggest an approximately 2-fold increase in the risk of NAION within 5 half-lives of PDE5 inhibitor use. It is not possible to determine whether these events are related directly to the use of PDE-5 inhibitors, to the patientâ€™s underlying vascular risk factors or anatomical defects, to a combination of these factors, or to other factors. Advise patients to seek immediate medical attention in the event of a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes while taking PDE-5 inhibitors, including sildenafil. Physicians should also discuss the increased risk of NAION with patients who have already experienced NAION in one eye, including whether such individuals could be adversely affected by use of vasodilators, such as PDE-5 inhibitors.</p>
<br><p>There are no controlled clinical data on the safety or efficacy of sildenafil in patients with <span class="product-label-link" type="condition" conceptid="4103381" conceptname="Retinitis pigmentosa">retinitis pigmentosa</span>, a minority whom have genetic disorders of retinal phosphodiesterases. Prescribe sildenafil with caution in these patients.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6 <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing Loss</span></h2>
<br><p class="First">Cases of sudden decrease or loss of hearing, which may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, have been reported in temporal association with the use of PDE-5 inhibitors, including sildenafil. In some of the cases, medical conditions and other factors were reported that may have played a role. In many cases, medical follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of sildenafil, to the patientâ€™s underlying risk factors for <span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">hearing loss</span>, a combination of these factors, or to other factors.<br><br>Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking PDE-5 inhibitors, including sildenafil.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7 Combination with other PDE-5 Inhibitors</h2>
<br><p class="First">Sildenafil is also marketed as VIAGRA<span class="Sup">Â®</span>. The safety and efficacy of combinations of sildenafil with VIAGRA or other PDE-5 inhibitors have not been studied. Inform patients taking sildenafil not to take VIAGRA or other PDE-5 inhibitors.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.8"></a><a name="section-5.8"></a><p></p>
<h2>5.8 <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span></h2>
<br><p class="First">Use sildenafil with caution in patients with anatomical deformation of the penis (e.g., angulation, cavernosal <span class="product-label-link" type="condition" conceptid="4012171" conceptname="Fibrosis">fibrosis</span>, or Peyronieâ€™s disease) or in patients who have conditions, which may predispose them to <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (e.g., <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span>, <span class="product-label-link" type="condition" conceptid="437233" conceptname="Multiple myeloma">multiple myeloma</span>, or <span class="product-label-link" type="condition" conceptid="315497" conceptname="Subacute leukemia">leukemia</span>). In the event of an erection that persists longer than 4 hours, the patient should seek immediate medical assistance. If <span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">priapism</span> (<span class="product-label-link" type="condition" conceptid="4213599" conceptname="Painful penile erection">painful erection</span> greater than 6 hours in duration) is not treated immediately, penile tissue damage and permanent loss of potency could result.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_5.9"></a><a name="section-5.9"></a><p></p>
<h2>5.9 Vaso-occlusive Crisis in Patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">Pulmonary Hypertension Secondary</span> to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">Sickle Cell Anemia</span></h2>
<br><p class="First">In a small, prematurely terminated study of patients with <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span> (PH) secondary to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell disease</span>, vaso-occlusive crises requiring hospitalization were more commonly reported by patients who received sildenafil than by those randomized to placebo. The effectiveness and safety of sildenafil in the treatment of PAH secondary to <span class="product-label-link" type="condition" conceptid="22281" conceptname="Hb SS disease">sickle cell anemia</span> has not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="Section_6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<br><p class="First">The following serious adverse events are discussed elsewhere in the labeling: </p>
<ul class="Disc">
<li>Mortality with pediatric use <span class="Italics">[<a href="#Section_5.1">see Warnings and Precautions (5.1)</a> and <a href="#Section_8.4">Use in Specific Populations (8.4)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">Hypotension</span> <span class="Italics">[<a href="#Section_5.2">see Warnings and Precautions (5.2)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">Vision loss</span> <span class="Italics">[<a href="#Section_5.5">see Warnings and Precautions (5.5)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="377889" conceptname="Hearing loss">Hearing loss</span> <span class="Italics">[<a href="#Section_5.6">see Warnings and Precautions (5.6)</a>] </span>
</li>
<li><span class="product-label-link" type="condition" conceptid="315586" conceptname="Priapism">Priapism</span> <span class="Italics">[<a href="#Section_5.8">see Warnings and Precautions (5.8)</a>] </span>
</li>
<li>Vaso-occlusive crisis <span class="Italics">[<a href="#Section_5.9">see Warnings and Precautions (5.9)</a>] </span>
</li>
</ul>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1 Clinical Trials Experience</h2>
<br><p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.<br><br>Safety data of sildenafil in adults were obtained from the 12-week, placebo-controlled clinical study (Study 1) and an open-label extension study in 277 sildenafil-treated patients with PAH, WHO Group I <span class="Italics">[</span><span class="Italics"><a href="#Section_14">see Clinical Studies (14)</a></span><span class="Italics">]</span>.<br><br>The overall frequency of discontinuation in sildenafil-treated patients on 20 mg three times a day was 3% and was the same for the placebo group.<br><br>In Study 1, the adverse reactions that were reported by at least 3% of sildenafil-treated patients (20 mg three times a day) and were more frequent in sildenafil-treated patients than in placebo-treated patients are shown in Table 1. Adverse reactions were generally transient and mild to moderate in nature.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 1. Most Common Adverse Reactions in Patients with PAH in Study 1 (More Frequent in Sildenafil-Treated Patients than Placebo-Treated Patients and Incidence â‰¥3% in Sildenafil-Treated Patients) 
			</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="justify" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo, %</span><br><span class="Bold">(n = 70)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Sildenafil</span><span class="Bold"> 20 mg three times a day, % <br>            (n = 69)</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo-</span><br><span class="Bold">Subtracted, %</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="318556" conceptname="Epistaxis">Epistaxis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1 <br>
</td>
<td class="Rrule" align="center" valign="top">9 <br>
</td>
<td class="Rrule" align="center" valign="top">8 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>
</td>
<td class="Rrule" align="center" valign="top">39 <br>
</td>
<td class="Rrule" align="center" valign="top">46 <br>
</td>
<td class="Rrule" align="center" valign="top">7 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">7 <br>
</td>
<td class="Rrule" align="center" valign="top">13 <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Flushing</span> <br>
</td>
<td class="Rrule" align="center" valign="top">4 <br>
</td>
<td class="Rrule" align="center" valign="top">10 <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">Insomnia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1 <br>
</td>
<td class="Rrule" align="center" valign="top">7 <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">Erythema</span> <br>
</td>
<td class="Rrule" align="center" valign="top">1 <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
<td class="Rrule" align="center" valign="top">5 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea exacerbated</span> <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
<td class="Rrule" align="center" valign="top">7 <br>
</td>
<td class="Rrule" align="center" valign="top">4 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">Rhinitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">0 <br>
</td>
<td class="Rrule" align="center" valign="top">4 <br>
</td>
<td class="Rrule" align="center" valign="top">4 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
<td class="Rrule" align="center" valign="top">9 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">Myalgia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">4 <br>
</td>
<td class="Rrule" align="center" valign="top">7 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Pyrexia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
<td class="Rrule" align="center" valign="top">6 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="201340" conceptname="Gastritis">Gastritis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">0 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">Sinusitis</span> <br>
</td>
<td class="Rrule" align="center" valign="top">0 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">Paresthesia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">0 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
<td class="Rrule" align="center" valign="top">3 <br>
</td>
</tr>
</tbody>
</table>
<p>At doses higher than the recommended 20 mg three times a day, there was a greater incidence of some adverse reactions including <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="442752" conceptname="Muscle pain">myalgia</span> and <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">visual disturbances</span>. <span class="product-label-link" type="condition" conceptid="374034" conceptname="Visual disturbance">Visual disturbances</span> were identified as mild and transient, and were predominately color-tinge to vision, but also increased sensitivity to light or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>.<br><br>The incidence of <span class="product-label-link" type="condition" conceptid="374025" conceptname="Retinal hemorrhage">retinal hemorrhage</span> with sildenafil 20 mg three times a day was 1.4% versus 0% placebo and for all sildenafil doses studied was 1.9% versus 0% placebo. The incidence of <span class="product-label-link" type="condition" conceptid="433778" conceptname="Orbital hemorrhage">eye hemorrhage</span> at both 20 mg three times a day and at all doses studied was 1.4% for sildenafil versus 1.4% for placebo. The patients experiencing these reactions had risk factors for <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> including concurrent anticoagulant therapy.<br><br>In a placebo-controlled fixed dose titration study (Study 2) of sildenafil (starting with recommended dose of 20 mg and increased to 40 mg and then 80 mg all three times a day) as an adjunct to intravenous epoprostenol in patients with PAH, the adverse reactions that were more frequent in the sildenafil + epoprostenol group than in the epoprostenol group (greater than 6% difference) are shown in Table 2 <span class="Italics">[<span class="Italics"><a href="#Section_14">see Clinical Studies (14)</a></span>]</span>.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 2. Adverse Reactions (%) in patients with PAH in Study 2 (incidence in Sildenafil + Epoprostenol group at least 6% greater than Epoprostenol group) 
			</span></caption>
<tfoot><tr class="First Last"><td colspan="4">* includes <span class="product-label-link" type="condition" conceptid="4094513" conceptname="Ankle edema">peripheral edema</span></td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="justify" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Sildenafil </span><span class="Bold">+ </span><span class="Bold">Epoprostenol</span><br><span class="Bold">(n = 134)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Epoprostenol</span><br><span class="Bold">(n = 131)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">(Sildenafil + Epoprostenol) </span><br><span class="Bold">minus Epoprostenol</span><span class="Bold"></span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span> <br>
</td>
<td class="Rrule" align="center" valign="top">57<br>
</td>
<td class="Rrule" align="center" valign="top">34<br>
</td>
<td class="Rrule" align="center" valign="top">23<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">Edema</span>*<br>
</td>
<td class="Rrule" align="center" valign="top">25<br>
</td>
<td class="Rrule" align="center" valign="top">13<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span> <br>
</td>
<td class="Rrule" align="center" valign="top">16<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">14<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="138525" conceptname="Pain in limb">Pain in extremity</span> <br>
</td>
<td class="Rrule" align="center" valign="top">17<br>
</td>
<td class="Rrule" align="center" valign="top">6<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">25<br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span> <br>
</td>
<td class="Rrule" align="center" valign="top">25<br>
</td>
<td class="Rrule" align="center" valign="top">18<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span> <br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
<td class="Rrule" align="center" valign="top">7<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Underline"><span class="Italics">Sildenafil I</span></span><span class="Underline"><span class="Italics">njection<br></span></span><br>Sildenafil injection was studied in a 66-patient, placebo-controlled study in patients with PAH at doses targeting plasma concentrations between 10 and 500 ng/mL (up to 8 times the exposure of the recommended dose). Adverse events with sildenafil injection were similar to those seen with oral tablets.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2 Postmarketing Experience</h2>
<br><p class="First">The following adverse reactions have been identified during post approval use of sildenafil (marketed for both PAH and <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.<br><span class="Bold"><br>Cardiovascular Events<br></span><br>In postmarketing experience with sildenafil at doses indicated for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>, serious cardiovascular, cerebrovascular, and vascular events, including <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, <span class="product-label-link" type="condition" conceptid="4317150" conceptname="Sudden cardiac death">sudden cardiac death</span>, <span class="product-label-link" type="condition" conceptid="4185572" conceptname="Ventricular arrhythmia">ventricular arrhythmia</span>, cerebrovascular <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>, transient ischemic attack, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="4301606" conceptname="Pulmonary hemorrhage">pulmonary hemorrhage</span>, and subarachnoid and <span class="product-label-link" type="condition" conceptid="376713" conceptname="Cerebral hemorrhage">intracerebral hemorrhages</span> have been reported in temporal association with the use of the drug. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of sildenafil without sexual activity. Others were reported to have occurred hours to days after use concurrent with sexual activity. It is not possible to determine whether these events are related directly to sildenafil, to sexual activity, to the patientâ€™s underlying cardiovascular disease, or to a combination of these or other factors.<br><span class="Bold"><br>Nervous system<br></span><br><span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Seizure</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizure</span> recurrence</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="Section_7"></a><a name="section-7"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<br><p class="First"><span class="Bold">Nitrates<br></span><br>Concomitant use of sildenafil with nitrates in any form is contraindicated <span class="Italics">[<a href="#Section_4">see Contraindications (4)</a>]</span>.<br><span class="Bold"><br>Ritonavir and other Potent CYP3A Inhibitors<br></span><br>Concomitant use of sildenafil with ritonavir and other potent CYP3A inhibitors is not recommended <span class="Italics">[<a href="#Section_12.3">see Clinical Pharmacology (12.3)</a>]</span>.<br><span class="Bold"><br>Other drugs that reduce blood pressure<br></span><span class="Italics"><br>Alpha blockers. </span>In drug-drug interaction studies, sildenafil (25 mg, 50 mg, or 100 mg) and the alpha-blocker doxazosin (4 mg or 8 mg) were administered simultaneously to patients with <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">benign prostatic hyperplasia</span> (BPH) stabilized on doxazosin therapy. In these study populations, mean additional reductions of supine systolic and diastolic blood pressure of 7/7 mmHg, 9/5 mmHg, and 8/4 mmHg, respectively, were observed. Mean additional reductions of standing blood pressure of 6/6 mmHg, 11/4 mmHg, and 4/5 mmHg, respectively, were also observed. There were infrequent reports of patients who experienced symptomatic <span class="product-label-link" type="condition" conceptid="319041" conceptname="Orthostatic hypotension">postural hypotension</span>. These reports included <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> and light-headedness, but not <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>.<br><span class="Italics"><br>Amlodipine. </span>When sildenafil 100 mg oral was co-administered with amlodipine, 5 mg or 10 mg oral, to hypertensive patients, the mean additional reduction on supine blood pressure was 8 mmHg systolic and 7 mmHg diastolic.<br><br>Monitor blood pressure when co-administering blood pressure lowering drugs with sildenafil <span class="Italics">[<a href="#Section_5.2">see Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="Section_8"></a><a name="section-8"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="Section_8.1"></a><a name="section-8.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<br><p class="First"><span class="Bold">Pregnancy Category B<br></span><br>There are no adequate and well-controlled studies of sildenafil in pregnant women. No evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span>, embryotoxicity, or fetotoxicity was observed in pregnant rats or rabbits dosed with sildenafil 200 mg/kg/day during organogenesis, a level that is, on a mg/m<span class="Sup">2 </span>basis, 32- and 68-times, respectively, the recommended human dose (RHD) of 20 mg three times a day. In a rat pre- and postnatal development study, the no-observed-adverse-effect dose was 30 mg/kg/day (equivalent to 5-times the RHD on a mg/m<span class="Sup">2 </span>basis).</p>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="Section_8.2"></a><a name="section-8.2"></a><p></p>
<h2>8.2 Labor and Delivery</h2>
<br><p class="First">The safety and efficacy of sildenafil during labor and delivery have not been studied.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="Section_8.3"></a><a name="section-8.3"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<br><p class="First">It is not known if sildenafil or its metabolites are excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when sildenafil is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="Section_8.4"></a><a name="section-8.4"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">In a randomized, double-blind, multi-center, placebo-controlled, parallel-group, dose-ranging study, 234 patients with PAH, aged 1 to 17 years, body weight greater than or equal to 8 kg, were randomized, on the basis of body weight, to three dose levels of sildenafil, or placebo, for 16 weeks of treatment. Most patients had mild to moderate symptoms at baseline: WHO Functional Class I (32%), II (51%), III (15%), or IV (0.4%). One-third of patients had primary PAH; two-thirds had secondary PAH (systemic-to-pulmonary shunt in 37%; surgical repair in 30%). Sixty-two percent of patients were female. Drug or placebo was administered three times a day. <br><br>The primary objective of the study was to assess the effect of sildenafil on exercise capacity as measured by cardiopulmonary exercise testing in pediatric patients developmentally able to perform the test (n = 115). Administration of sildenafil did not result in a statistically significant improvement in exercise capacity in those patients. No patients died during the 16-week controlled study.<br><br>After completing the 16-week controlled study, a patient originally randomized to sildenafil remained on his/her dose of sildenafil or, if originally randomized to placebo, was randomized to low-, medium-, or high-dose sildenafil. After all patients completed 16 weeks of follow-up in the controlled study, the blind was broken and doses were adjusted as clinically indicated. Patients treated with sildenafil were followed for a median of 4.6 years (range 2 days to 8.6 years). Mortality during the long-term study, by originally assigned dose, is shown in Figure 1:<br><span class="Bold"><br>Figure 1: Kaplan-Meier Plot of Mortality by Sildenafil Dose<br></span><img alt="Figure 1: Kaplan-Meier Plot of Mortality by Sildenafil Dose" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig1.jpg"><br>During the study, there were 42 reported <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, with 37 of these <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span> reported prior to a decision to titrate subjects to a lower dosage because of a finding of increased mortality with increasing sildenafil doses. For the survival analysis which included 37 <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">deaths</span>, the hazard ratio for high dose compared to low dose was 3.9, p = 0.007. Causes of <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> were typical of patients with PAH. Use of sildenafil, particularly chronic use, is not recommended in children.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="Section_8.5"></a><a name="section-8.5"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<br><p class="First">Clinical studies of sildenafil did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy <span class="Italics">[<a href="#Section_12.3">see Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.6"></a><a name="section-8.6"></a><p></p>
<h2>8.6 Patients with <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span></h2>
<br><p class="First">No dose adjustment for mild to moderate impairment is required. Severe impairment has not been studied <span class="Italics">[<a href="#Section_12.3">see Clinical Pharmacology (12.3)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="Section_8.7"></a><a name="section-8.7"></a><p></p>
<h2>8.7 Patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span></h2>
<br><p class="First">No dose adjustment is required (including severe impairment CLcr &lt; 30 mL/min) <span class="Italics">[<a href="#Section_12.3">see Clinical Pharmacology (12.3)</a>].</span></p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="Section_10"></a><a name="section-9"></a><p></p>
<h1>10 OVERDOSAGE</h1>
<br><p class="First">In studies with healthy volunteers of single doses up to 800 mg, adverse events were similar to those seen at lower doses but rates and severities were increased.<br><br>In cases of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, standard supportive measures should be adopted as required. Renal dialysis is not expected to accelerate clearance as sildenafil is highly bound to plasma proteins and it is not eliminated in the urine.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="Section_11"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<br><p class="First">Sildenafil injection, phosphodiesterase-5 (PDE-5) inhibitor, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE-5). Sildenafil is also marketed as VIAGRA<span class="Sup">Â® </span>for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>.<br><br>Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1<span class="Italics">H</span>-pyrazolo [4,3-<span class="Italics">d</span>] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate and has the following structural formula:<br><img alt="Sildenafil Citrate Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-str.jpg"><br>Sildenafil citrate USP is a white or almost white slightly hygroscopic crystalline powder with a solubility of 3.5 mg/mL in water and a molecular weight of 666.7.<br><br>Sildenafil injection is supplied as a clear, colorless, sterile, ready to use solution in a single-use vial containing 10 mg/12.5 mL of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate USP equivalent to 0.8 mg sildenafil, 50.5 mg dextrose and water for injection.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="Section_12"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="Section_12.1"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<br><p class="First">Sildenafil is an inhibitor of cGMP specific phosphodiesterase type-5 (PDE-5) in the smooth muscle of the pulmonary vasculature, where PDE-5 is responsible for degradation of cGMP. Sildenafil, therefore, increases cGMP within pulmonary vascular smooth muscle cells resulting in relaxation. In patients with PAH, this can lead to vasodilation of the pulmonary vascular bed and, to a lesser degree, <span class="product-label-link" type="condition" conceptid="4237053" conceptname="Vasodilatation">vasodilatation</span> in the systemic circulation.<br><br>Studies <span class="Italics">in vitro</span> have shown that sildenafil is selective for PDE-5. Its effect is more potent on PDE-5 than on other known phosphodiesterases (10-fold for PDE6, greater than 80-fold for PDE1, greater than 700-fold for PDE2, PDE3, PDE4, PDE7, PDE8, PDE9, PDE10, and PDE11). The approximately 4,000-fold selectivity for PDE-5 versus PDE3 is important because PDE3 is involved in control of cardiac contractility. Sildenafil is only about 10-fold as potent for PDE-5 compared to PDE6, an enzyme found in the retina and involved in the phototransduction pathway of the retina. This lower selectivity is thought to be the basis for abnormalities related to color vision observed with higher doses or plasma levels <span class="Italics">[<a href="#Section_12.2">see Clinical Pharmacology (12.2)</a>]</span>.<br><br>In addition to pulmonary vascular smooth muscle and the corpus cavernosum, PDE-5 is also found in other tissues including vascular and visceral smooth muscle and in platelets. The inhibition of PDE-5 in these tissues by sildenafil may be the basis for the enhanced platelet anti-aggregatory activity of nitric oxide observed <span class="Italics">in vitro</span>, and the mild peripheral arterial-venous dilatation <span class="Italics">in vivo</span>.</p>
</div>
<div class="Section" data-sectionCode="43681-6">
<a name="Section_12.2"></a><a name="section-11.2"></a><p></p>
<h2>12.2 Pharmacodynamics</h2>
<p class="First"><span class="Bold">Effects of Sildenafil on Hemodynamic Measures<br></span><br>Patients on all sildenafil doses achieved a statistically significant reduction in mean pulmonary arterial pressure (mPAP) compared to those on placebo in a study with no background vasodilatorsÂ <span class="Italics">[<a href="#Section_14">Study 1 in Clinical Studies (14)</a>].</span>Â Data on other hemodynamic measures for the sildenafil 20 mg three times a day and placebo dosing regimens is displayed in Table 3. The relationship between these effects and improvements in 6-minute walk distance is unknown.</p>
<br><table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 3. Changes from Baseline in Hemodynamic Parameters at Week 12 [mean (95% CI)] for the Sildenafil 20 mg Three Times a Day and Placebo Group 
			</span></caption>
<tfoot><tr class="First Last"><td align="left" colspan="3">
<br>mPAP = mean pulmonary arterial pressure; PVR = pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>; SVR = systemic <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span>; RAP = right atrial pressure; CO = <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span>; HR = heart rate<br>        * The number of patients per treatment group varied slightly for each parameter due to missing assessments.<br>
</td></tr></tfoot>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="center" valign="top"></td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(n = 65)</span>* <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">Sildenafil 20 mg</span><br><span class="Bold">three times a day</span><br><span class="Bold">(n = 65)</span>* <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">mPAP (mmHg)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">0.6 (-0.8, 2) <br>
</td>
<td class="Rrule" align="center" valign="top">-2.1 (-4.3, 0) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">PVR (dynâ€¢s/cm<span class="Sup">5</span>)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">49 (-54, 153) <br>
</td>
<td class="Rrule" align="center" valign="top">-122 (-217, -27) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">SVR (dynâ€¢s/cm<span class="Sup">5</span>)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">-78 (-197, 41) <br>
</td>
<td class="Rrule" align="center" valign="top">-167 (-307, -26) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">RAP (mmHg)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">0.3 (-0.9, 1.5) <br>
</td>
<td class="Rrule" align="center" valign="top">-0.8 (-1.9, 0.3) <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">CO (L/min)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">-0.1 (-0.4, 0.2) <br>
</td>
<td class="Rrule" align="center" valign="top">0.4 (0.1, 0.7) <br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="center" valign="top">
<span class="Bold">HR (beats/min)</span><span class="Bold"></span><br>
</td>
<td class="Rrule" align="center" valign="top">-1.3 (-4.1, 1.4) <br>
</td>
<td class="Rrule" align="center" valign="top">-3.7 (-5.9, -1.4) <br>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Effects of Sildenafil on Blood Pressure </span></p>
<br><p>Single oral doses of sildenafil 100 mg administered to healthy volunteers produced decreases in supine blood pressure (mean maximum decrease in systolic/diastolic blood pressure of 8/5 mmHg). The decrease in blood pressure was most notable approximately 1 to 2 hours after dosing, and was not different from placebo at 8 hours. Similar effects on blood pressure were noted with 25 mg, 50 mg and 100 mg doses of sildenafil, therefore the effects are not related to dose or plasma levels within this dosage range. Larger effects were recorded among patients receiving concomitant nitratesÂ <span class="Italics">[<a href="#Section_4">see Contraindications (4)</a>]</span>. </p>
<br><p>Single oral doses of sildenafil up to 100 mg in healthy volunteers produced no clinically relevant effects on ECG. After chronic dosing of 80 mg three times a day to patients with PAH, no clinically relevant effects on ECG were reported. </p>
<br><p>After chronic dosing of 80 mg three times a day sildenafil to healthy volunteers, the largest mean change from baseline in supine systolic and supine diastolic blood pressures was a decrease of 9 mmHg and 8.4 mmHg, respectively. </p>
<br><p>After chronic dosing of 80 mg three times a day sildenafil to patients with systemic <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, the mean change from baseline in systolic and diastolic blood pressures was a decrease of 9.4 mmHg and 9.1 mmHg, respectively. </p>
<br><p>After chronic dosing of 80 mg three times a day sildenafil to patients with PAH, lesser reductions than above in systolic and diastolic blood pressures were observed (a decrease in both of 2 mmHg).</p>
<br><p><span class="Bold">Effects of Sildenafil on Vision </span></p>
<br><p>At single oral doses of 100 mg and 200 mg, transient dose-related impairment of color discrimination (blue/green) was detected using the Farnsworth-Munsell 100-hue test, with peak effects near the time of peak plasma levels. This finding is consistent with the inhibition of PDE6, which is involved in phototransduction in the retina. An evaluation of visual function at doses up to 200 mg revealed no effects of sildenafil on visual acuity, intraocular pressure, or pupillometry.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="Section_12.3"></a><a name="section-11.3"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<br><p class="First"><span class="Bold">Absorption and Distribution<br></span><br>Sildenafil is rapidly absorbed after oral administration, with a mean absolute bioavailability of 41% (25 to 63%). Maximum observed plasma concentrations are reached within 30 to 120 minutes (median 60 minutes) of oral dosing in the fasted state. When sildenafil is taken with a high-fat meal, the rate of absorption is reduced, with a mean delay in T<span class="Sub">max</span> of 60 minutes and a mean reduction in C<span class="Sub">max</span> of 29%. The mean steady state volume of distribution (V<span class="Sub">ss</span>) for sildenafil is 105 L, indicating distribution into the tissues. Sildenafil and its major circulating N-desmethyl metabolite are both approximately 96% bound to plasma proteins. Protein binding is independent of total drug concentrations.<br><span class="Bold"><br>Metabolism and Excretion<br></span><br>Sildenafil is cleared predominantly by the CYP3A (major route) and cytochrome P450 2C9 (CYP2C9, minor route) hepatic microsomal isoenzymes. The major circulating metabolite results from N-desmethylation of sildenafil, and is, itself, further metabolized. This metabolite has a phosphodiesterase selectivity profile similar to sildenafil and an <span class="Italics">in vitro</span> potency for PDE-5 approximately 50% of the parent drug. In healthy volunteers, plasma concentrations of this metabolite are approximately 40% of those seen for sildenafil, so that the metabolite accounts for about 20% of sildenafilâ€™s pharmacologic effects. In patients with PAH, however, the ratio of the metabolite to sildenafil is higher. Both sildenafil and the active metabolite have terminal half-lives of about 4 hours.<br><br>After either oral or intravenous administration, sildenafil is excreted as metabolites predominantly in the feces (approximately 80% of the administered oral dose) and to a lesser extent in the urine (approximately 13% of the administered oral dose).<br><br>Sildenafil Injection: The pharmacokinetic profile of sildenafil has been characterized following intravenous administration. A 10 mg dose of sildenafil injection is predicted to provide a pharmacological effect of sildenafil and its N-desmethyl metabolite equivalent to that of a 20 mg oral dose.<br><span class="Bold"><br>Population Pharmacokinetics<br></span><br>Age, gender, race, and renal and hepatic function were included as factors assessed in the population pharmacokinetic model to evaluate sildenafil pharmacokinetics in patients with PAH. The dataset available for the population pharmacokinetic evaluation contained a wide range of demographic data and laboratory parameters associated with hepatic and renal function. None of these factors had a significant impact on sildenafil pharmacokinetics in patients with PAH.<br><br>In patients with PAH, the average steady-state concentrations were 20 to 50% higher when compared to those of healthy volunteers. There was also a doubling of C<span class="Sub">min</span> levels compared to healthy volunteers. Both findings suggest a lower clearance and/or a higher oral bioavailability of sildenafil in patients with PAH compared to healthy volunteers.<br><span class="Underline"><br>Geriatric Patients<br></span><br>Healthy elderly volunteers (65 years or over) had a reduced clearance of sildenafil, resulting in approximately 84% and 107% higher plasma concentrations of sildenafil and its active N-desmethyl metabolite, respectively, compared to those seen in healthy younger volunteers (18 to 45 years). Due to age-differences in plasma protein binding, the corresponding increase in the AUC of free (unbound) sildenafil and its active N-desmethyl metabolite were 45% and 57%, respectively.<br><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span><br></span><br>In volunteers with mild (CLcr = 50 to 80 mL/min) and moderate (CLcr = 30 to 49 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, the pharmacokinetics of a single oral dose of sildenafil (50 mg) was not altered. In volunteers with severe (CLcr less than 30 mL/min) <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>, sildenafil clearance was reduced, resulting in approximately doubling of AUC and C<span class="Sub">max</span> compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. In addition, N-desmethyl metabolite AUC and C<span class="Sub">max </span>values were significantly increased 200% and 79%, respectively, in subjects with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> compared to subjects with normal renal function.<br><span class="Underline"><br><span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">Hepatic Impairment</span><br></span><br>In volunteers with mild to moderate <span class="product-label-link" type="condition" conceptid="4064161" conceptname="Cirrhosis of liver">hepatic cirrhosis</span> (Child-Pugh class A and B), sildenafil clearance was reduced, resulting in increases in AUC (84%) and C<span class="Sub">max</span> (47%) compared to age-matched volunteers with no <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span>. Patients with severe <span class="product-label-link" type="condition" conceptid="4212540" conceptname="Chronic liver disease">hepatic impairment</span> (Child-Pugh class C) have not been studied.<br><span class="Bold"><br>Drug Interaction Studies<br></span><span class="Bold"><span class="Italics"><br>In vitro </span></span><span class="Bold">studies<br></span><br>Sildenafil metabolism is principally mediated by the CYP3A (major route) and CYP2C9 (minor route) cytochrome P450 isoforms. Therefore, inhibitors of these isoenzymes may reduce sildenafil clearance and inducers of these isoenzymes may increase sildenafil clearance.<br><br>Sildenafil is a weak inhibitor of the cytochrome P450 isoforms 1A2, 2C9, 2C19, 2D6, 2E1 and 3A (IC50 greater than 150 Î¼M).<br><br>Sildenafil is not expected to affect the pharmacokinetics of compounds which are substrates of these CYP enzymes at clinically relevant concentrations.<br><span class="Bold"><span class="Italics"><br>In vivo </span>studies<br></span><br>The effects of other drugs on sildenafil pharmacokinetics and the effects of sildenafil on the exposure to other drugs are shown in Figure 2 and Figure 3, respectively.<br><span class="Bold"><br>Figure 2. Effects of Other Drugs on Sildenafil Pharmacokinetics<br><img alt="Figure 2. Effects of Other Drugs on Sildenafil Pharmacokinetics" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig2.jpg"></span></p>
<p><span class="Bold"><br>Figure 3. Effects of Sildenafil on Other Drugs<br><img alt="Figure 3. Effects of Sildenafil on Other Drugs" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig3.jpg"><br></span><span class="Underline"><br></span><span class="Underline">CYP3A Inhibitors and Beta Blockers<br></span><br>Population pharmacokinetic analysis of data from patients in clinical trials indicated an approximately 30% reduction in sildenafil clearance when it was co-administered with mild/moderate CYP3A inhibitors and an approximately 34% reductions in sildenafil clearance when co-administered with beta-blockers. Sildenafil exposure at a dose of 80 mg three times a day without concomitant medication is shown to be 5-fold the exposure at a dose of 20 mg three times a day. This concentration range covers the same increased sildenafil exposure observed in specifically-designed drug interaction studies with CYP3A inhibitors (except for potent inhibitors such as ketoconazole, itraconazole, and ritonavir).<br><br>Sildenafil Injection: Predictions based on a pharmacokinetic model suggest that drug-drug interactions with CYP3A inhibitors will be less than those observed after oral sildenafil administration.<br><br><span class="Underline">CYP3A4 inducers<br></span><br>Concomitant administration of potent CYP3A inducers is expected to cause substantial decreases in plasma levels of sildenafil.<br><br>Population pharmacokinetic analysis of data from patients in clinical trials indicated approximately 3-fold the sildenafil clearance when it was co-administered with mild CYP3A inducers.<br><br><span class="Underline">Epoprostenol<br></span><br>The mean reduction of sildenafil (80 mg three times a day) bioavailability when co-administered with epoprostenol was 28%, resulting in about 22% lower mean average steady state concentrations. Therefore, the slight decrease of sildenafil exposure in the presence of epoprostenol is not considered clinically relevant. The effect of sildenafil on epoprostenol pharmacokinetics is not known.<br><br>No significant interactions were shown with tolbutamide (250 mg) or warfarin (40 mg), both of which are metabolized by CYP2C9.<br><span class="Underline"><br>Alcohol<br></span><br>Sildenafil (50 mg) did not potentiate the hypotensive effect of alcohol in healthy volunteers with mean maximum blood alcohol levels of 0.08%.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="Section_13"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="Section_13.1"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<br><p class="First">Sildenafil was not carcinogenic when administered to rats for up to 24 months at 60 mg/kg/day, a dose resulting in total systemic exposure (AUC) to unbound sildenafil and its major metabolite 33 and 37 times, for male and female rats respectively, the human exposure at the RHD of 20 mg three times a day. Sildenafil was not carcinogenic when administered to male and female mice for up to 21 and 18 months, respectively, at doses up to a maximally tolerated level of 10 mg/kg/day, a dose equivalent to the RHD on a mg/m<span class="Sup">2 </span>basis.<br><br>Sildenafil was negative in <span class="Italics">in vitro </span>bacterial and Chinese hamster ovary cell assays to detect mutagenicity, and <span class="Italics">in vitro </span>human <span class="product-label-link" type="condition" conceptid="4254663" conceptname="Lymphocyte count">lymphocytes</span> and <span class="Italics">in vivo </span>mouse micronucleus assays to detect clastogenicity.<br><br>There was no impairment of fertility in male or female rats given up to 60 mg sildenafil/kg/day, a dose producing a total systemic exposure (AUC) to unbound sildenafil and its major metabolite of 19 and 38 times for males and females, respectively, the human exposure at the RHD of 20 mg three times a day.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="Section_14"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<br><p class="First"><span class="Bold">Studies of Adults with <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">Pulmonary Arterial Hypertension</span><br></span><span class="Bold"><br>Study 1 (Sildenafil monotherapy (20 mg, 40 mg, and 80 mg three times a day))<br></span><br>A randomized, double-blind, placebo-controlled study of sildenafil (Study 1) was conducted in 277 patients with PAH (defined as a mean pulmonary artery pressure of greater than or equal to 25 mmHg at rest with a pulmonary capillary wedge pressure less than 15 mmHg). Patients were predominantly World Health Organization (WHO) functional classes II-III. Allowed background therapy included a combination of anticoagulants, digoxin, calcium channel blockers, diuretics, and oxygen. The use of prostacyclin analogues, endothelin receptor antagonists, and arginine supplementation were not permitted. Subjects who had failed to respond to bosentan were also excluded. Patients with left ventricular <span class="product-label-link" type="condition" conceptid="4108582" conceptname="Left ventricular ejection fraction">ejection fraction</span> less than 45% or left ventricular shortening fraction less than 0.2 also were not studied.<br><br>Patients were randomized to receive placebo (n=70) or sildenafil 20 mg (n = 69), 40 mg (n = 67) or 80 mg (n = 71) three times a day for a period of 12 weeks. They had either <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">primary pulmonary hypertension</span> (PPH) (63%), PAH associated with CTD (30%), or PAH following surgical repair of left-to-right congenital heart lesions (7%). The study population consisted of 25% men and 75% women with a mean age of 49 years (range: 18 to 81 years) and baseline 6-minute walk distance between 100 and 450 meters (mean 343).<br><br>The primary efficacy endpoint was the change from baseline at week 12 (at least 4 hours after the last dose) in the 6-minute walk distance. Placebo-corrected mean increases in walk distance of 45 to 50 meters were observed with all doses of sildenafil. These increases were significantly different from placebo, but the sildenafil dose groups were not different from each other (see Figure 4), indicating no additional clinical benefit from doses higher than 20 mg three times a day. The improvement in walk distance was apparent after 4 weeks of treatment and was maintained at week 8 and week 12.<br><span class="Bold"><br>Figure 4. Change from Baseline in 6-Minute Walk Distance (meters) at Weeks 4, 8, and 12 in Study 1: Mean (95% Confidence Interval)<br></span><img alt="Figure 4. Change from Baseline in 6-Minute Walk Distance (meters) at Weeks 4, 8, and 12 in Study 1: Mean (95% Confidence Interval)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig4.jpg"><br><br>Figure 5 displays subgroup efficacy analyses in Study 1 for the change from baseline in 6-Minute Walk Distance at Week 12 including baseline walk distance, disease etiology, functional class, gender, age, and hemodynamic parameters.<br><span class="Bold"><br>Figure 5. Placebo-Corrected Change From Baseline in 6-Minute Walk Distance (meters) at Week 12 by study subpopulation in Study 1: Mean (95% Confidence Interval)<br></span><span class="Underline"><img alt="Figure 5. Placebo-Corrected Change From Baseline in 6-Minute Walk Distance (meters) at Week 12 by study subpopulation in study 1: Mean (95% Confidence Interval)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig5.jpg"><br>Key:</span> PAH = <span class="product-label-link" type="condition" conceptid="4013643" conceptname="Pulmonary arterial hypertension">pulmonary arterial hypertension</span>; CTD = connective tissue disease; PH = <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>; PAP = pulmonary arterial pressure; PVRI = pulmonary <span class="product-label-link" type="condition" conceptid="4089490" conceptname="Vascular resistance">vascular resistance</span> index; TID = three times daily.<br><br>Of the 277 treated patients, 259 entered a long-term, uncontrolled extension study. At the end of 1 year, 94% of these patients were still alive. Additionally, walk distance and functional class status appeared to be stable in patients taking sildenafil. Without a control group, these data must be interpreted cautiously.<br><span class="Bold"><br>Study 2 (Sildenafil co-administered with epoprostenol)<br></span><br>A randomized, double-blind, placebo controlled study (Study 2) was conducted in 267 patients with PAH who were taking stable doses of intravenous epoprostenol. Patients had to have a mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg and a pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg at rest via right heart catheterization within 21 days before randomization, and a baseline 6-minute walk test distance greater than or equal to 100 meters and less than or equal to 450 meters (mean 349 meters). Patients were randomized to placebo or sildenafil (in a fixed titration starting from 20 mg, to 40 mg and then 80 mg, three times a day) and all patients continued intravenous epoprostenol therapy.<br><br>At baseline patients had PPH (80%) or PAH secondary to CTD (20%); WHO functional class I (1%), II (26%), III (67%), or IV (6%); and the mean age was 48 years, 80% were female, and 79% were Caucasian.<br><br>There was a statistically significant greater increase from baseline in 6-minute walk distance at Week 16 (primary endpoint) for the sildenafil group compared with the placebo group. The mean change from baseline at Week 16 (last observation carried forward) was 30 meters for the sildenafil group compared with 4 meters for the placebo group giving an adjusted treatment difference of 26 meters (95% CI: 10.8, 41.2) (p = 0.0009).<br><br>Patients on sildenafil achieved a statistically significant reduction in mPAP compared to those on placebo. A mean placebo-corrected treatment effect of -3.9 mmHg was observed in favor of sildenafil (95% CI: -5.7, -2.1) (p = 0.00003).<br><br>Time to clinical worsening of PAH was defined as the time from randomization to the first occurrence of a clinical worsening event (<span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span>, lung transplantation, initiation of bosentan therapy, or clinical deterioration requiring a change in epoprostenol therapy). Table 4 displays the number of patients with clinical worsening events in Study 2. Kaplan-Meier estimates and a stratified log-rank test demonstrated that placebo-treated patients were 3 times more likely to experience a clinical worsening event than sildenafil-treated patients and that sildenafil-treated patients experienced a significant delay in time to clinical worsening versus placebo-treated patients (p = 0.0074). Kaplan-Meier plot of time to clinical worsening is presented in Figure 6.</p>
<table border="0" cellpadding="0" cellspacing="0" width="100%">
<caption><span>Table 4. Clinical Worsening Events in Study 2</span></caption>
<tbody class="Headless">
<tr class="Botrule First">
<td class="Lrule Rrule" align="justify" valign="top">Â <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Placebo</span><br><span class="Bold">(N = 131)</span><br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">
<span class="Bold">Sildenafil </span><br><span class="Bold">(N = 134)</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  Number of subjects with clinical worsening first event <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">23<br>Â <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">8<br>Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">First Event</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">All Events</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">First Event</span><br>
</td>
<td class="Rrule" align="center" valign="top">
<span class="Bold">All Events</span><br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span>, n <br>
</td>
<td class="Rrule" align="center" valign="top">3<br>
</td>
<td class="Rrule" align="center" valign="top">4<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  Lung Transplantation, n <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  Hospitalization due to PAH, n <br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">11<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
<td class="Rrule" align="center" valign="top">8<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â  Clinical deterioration resulting in: <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
<td class="Rrule" align="center" valign="top">Â <br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â Â Â Â Â Â Â Â Â Â  Change of Epoprostenol Dose, n <br>
</td>
<td class="Rrule" align="center" valign="top">9<br>
</td>
<td class="Rrule" align="center" valign="top">16<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">2<br>
</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="justify" valign="top">Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Initiation of Bosentan, n <br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">1<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
<td class="Rrule" align="center" valign="top">0<br>
</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="justify" valign="top">Â  Proportion Worsened 95% Confidence Interval <br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.187<br>(0.12 to 0.26)<br>
</td>
<td class="Rrule" align="center" colspan="2" valign="top">0.062<br>(0.02 to 0.1)<br>
</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Figure 6. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in Study 2<br></span></p>
<br><div class="Figure"><img alt="Figure 6. Kaplan-Meier Plot of Time (in Days) to Clinical Worsening of PAH in Study 2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig6.jpg"></div>
<br><p>Improvements in WHO functional class for PAH were also demonstrated in subjects on sildenafil compared to placebo. More than twice as many sildenafil-treated patients (36%) as placebo-treated patients (14%) showed an improvement in at least one functional New York Heart Association (NYHA) class for PAH.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="Section_16"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<br><p class="First">Sildenafil injection is supplied as a clear, colorless, sterile, ready to use solution containing 10 mg sildenafil/12.5 mL presented in a single-use glass vial.<br><br>Single-use Vials in a Carton of 1Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  NDC 55150-166-13<br><span class="Bold"><br>Store at</span> 20Â° to 25Â°C (68Â° to 77Â°F). [See USP Controlled Room Temperature.]<br><br>The vial stopper is not made with natural rubber latex.<br><span class="Bold"><br>Sterile, Nonpyrogenic</span></p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="Section_17"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<br><ul class="Disc">
<li>Inform patients of contraindication of sildenafil with regular and/or intermittent use of organic nitrates. </li>
<li>Inform patients that sildenafil is also marketed as VIAGRA for <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">erectile dysfunction</span>. Advise patients taking sildenafil not to take VIAGRA or other PDE-5 inhibitors. </li>
<li>Advise patients to seek immediate medical attention for a sudden <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> in one or both eyes while taking sildenafil. Such an event may be a sign of NAION. </li>
<li>Advise patients to seek prompt medical attention in the event of sudden decrease or loss of hearing while taking sildenafil. These events may be accompanied by <span class="product-label-link" type="condition" conceptid="377575" conceptname="Tinnitus">tinnitus</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>. </li>
</ul>
<p class="First">VIAGRA<span class="Sup">Â®</span> is a registered trademark of Pfizer Ireland.<br><br>MAALOX<span class="Sup">Â®</span> is a registered trademark of Novartis Consumer Health, Inc.<br><br>Manufactured for:<br><span class="Bold">AuroMedics Pharma LLC<br></span>6 Wheeling Road<br>Dayton, NJ 08810<br><br>Manufactured by:<br><span class="Bold">Aurobindo Pharma Limited<br></span>IDA, Pashamylaram - 502307<br>India<br><br>Revised:Â June 2015</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_19"></a><a name="section-16"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL Container Label</h1>
<br><p class="First">Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">NDC 55150-166-13</span><br><span class="Bold">Sildenafil <br>Injection</span><br><span class="Bold">10Â mg per 12.5 mL<br><span class="Bold">(0.8Â mg / mL)</span><br><span class="Bold">For IntravenousÂ Use</span><br><span class="Bold">Discard Unused Portion<br></span>Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Rx onlyÂ Â <br><span class="Bold">12.5 mL sterile single-use vial</span><br><span class="Bold"><br><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL Container Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig7.jpg"></span></span></p>
<br><br><span class="Bold"></span>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="Section_20"></a><a name="section-17"></a><p></p>
<h1>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL Container-Carton (1 Vial)</h1>
<br><br><p class="First">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â <span class="Bold">NDC 55150-166-13</span><br><span class="Bold">Sildenafil<br>Injection</span><br><span class="Bold">10Â mg per 12.5 mL</span><br><span class="Bold">(0.8Â mg / mL)</span><br><span class="Bold">For IntravenousÂ Use</span><br><span class="Bold">Discard Unused Portion</span><br><span class="Bold">Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â Â  Rx only</span>Â <br><span class="Bold">12.5 mL sterile single-use vial</span><br><span class="Bold">AUROMEDICS</span></p>
<br><br><div class="Figure"><img alt="PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 10 mg per 12.5 mL Container-Carton (1 Vial)" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=bb92d686-a81e-4b91-8048-693af0534cb3&amp;name=sildenafil-fig8.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>SILDENAFILÂ 		
					</strong><br><span class="contentTableReg">sildenafil citrate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:55150-166</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>SILDENAFIL CITRATE</strong> (SILDENAFIL) </td>
<td class="formItem">SILDENAFIL</td>
<td class="formItem">10Â mg Â inÂ 12.5Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>DEXTROSE MONOHYDRATE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:55150-166-13</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">12.5 mL in 1 VIAL, SINGLE-USE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA203988</td>
<td class="formItem">04/01/2015</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>AuroMedics Pharma LLC
							(968961354)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">918917626</td>
<td class="formItem">API MANUFACTURE(55150-166)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Aurobindo Pharma Limited</td>
<td class="formItem"></td>
<td class="formItem">650498244</td>
<td class="formItem">ANALYSIS(55150-166), MANUFACTURE(55150-166)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>9999a6f3-fe0b-4a7a-bfcf-7bd314566075</div>
<div>Set id: bb92d686-a81e-4b91-8048-693af0534cb3</div>
<div>Version: 2</div>
<div>Effective Time: 20150629</div>
</div>
</div>Â <div class="DistributorName">AuroMedics Pharma LLC</div></p>
</body></html>
